drugset

drugset / Trial / NCT02980692

Efficacy and Safety Study of SUNPG1623

NCT02980692 ↗

Phase 2 Completed 391 enrolled Sun Pharmaceutical Industries, Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled, multiple-dose, phase 2b study to demonstrate the safety and efficacy of SUNPG1623

Timeline

Start: 2017-04-19
Primary completion: 2019-03-01
Completion: 2019-09-24

Publications

Mease PJ, Chohan S, Fructuoso FJG, Luggen ME, Rahman P, Raychaudhuri SP, Chou RC, Mendelsohn AM, Rozzo SJ, Gottlieb A. Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study. Ann Rheum Dis. 2021 Sep;80(9):1147-1157. doi: 10.1136/annrheumdis-2020-219014. Epub 2021 May 13.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tildrakizumab	Monoclonal antibody	20 mg	Other
Subject	Tildrakizumab	Monoclonal antibody	100 mg	Other
Subject	Tildrakizumab	Monoclonal antibody	200 mg	Other

Indications